Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
AnaptysBio reports a royalty-focused Q1 2026 with a wider loss as it prepares for a spin-off of its drug development business. Collaboration revenue was $25.6 million, entirely from non-cash royalties on GSK’s Jemperli and Zejula. Research and development expense fell to $34.0 million as late-stage programs wound down, while general and administrative costs rose to $26.2 million, driven by legal spending and separation-related costs.
The company recorded a net loss of $52.9 million and significant non-cash interest expense of $20.9 million on royalty monetization liabilities tied to Jemperli and Zejula. Cash, cash equivalents and investments totaled $286.5 million as of March 31, 2026, and management believes this will fund operations for at least 12 months. On April 20, 2026, after quarter-end, AnaptysBio completed the spin-off of First Tracks Biotherapeutics, retaining a royalty-management focus around Jemperli and its imsidolimab collaboration with Vanda.
AnaptysBio, Inc. reported first-quarter 2026 results and highlighted its transition to a royalty-focused business following the spin-off of First Tracks Biotherapeutics. The company now manages financial collaborations for Jemperli with GSK and imsidolimab with Vanda, targeting an EBIT margin greater than 95% with streamlined operations.
Collaboration revenue was $25.6 million for the quarter, down from $27.8 million a year earlier, as prior Vanda license revenue rolled off but Jemperli royalties grew 44% from $17.2 million to $24.7 million. AnaptysBio posted a net loss of $52.9 million, or $1.84 per share, compared with a $39.3 million loss in the prior-year period.
Cash, cash equivalents and investments totaled $286.5 million as of March 31, 2026, versus $311.6 million at year-end 2025. The company announced a $100 million stock repurchase plan expiring December 31, 2026, and continues to carry a liability of $263.7 million related to the sale of future Jemperli royalties. Management reiterated expectations of more than $390 million in annualized Jemperli royalties payable to AnaptysBio as early as 2029 based on GSK’s peak sales guidance, and noted a December 12, 2026 FDA target action date for imsidolimab in generalized pustular psoriasis.
AnaptysBio, Inc. appointed Christopher M. Murphy as Chief Financial Officer effective May 11, 2026, serving as an independent contractor under a consulting agreement. He will receive monthly consulting fees of $42,916.66, an annual target cash bonus opportunity of up to 40% of total annual consulting fees, and an equity grant valued at $1,750,000 in restricted stock units vesting over four years.
If the agreement is terminated without cause, he is eligible for nine months of continued fees, or twelve months plus bonus-related payments and full vesting of equity awards if this occurs in connection with a qualifying corporate transaction. The Board also appointed Owen Hughes as a Class I director effective May 11, 2026, with an initial grant of 11,250 restricted stock units vesting over three years.
GRAY SUSANNAH reported acquisition or exercise transactions in this Form 4 filing.
AnaptysBio director Susannah Gray received a grant of 11,250 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of AnaptysBio common stock for no cash consideration upon settlement.
One third of the RSUs vest on April 27, 2027, with the remaining units vesting in equal annual installments, as long as Gray continues providing services to the company on each vesting date.
AnaptysBio, Inc. filed Amendment No. 1 to its annual report to add detailed disclosures on directors, executive officers, governance, compensation and ownership, instead of using a separate proxy statement. The filing updates board class composition following director departures so that six directors are evenly split across three staggered classes, and confirms committee memberships and independence.
The amendment describes 2025 non‑employee director compensation, including cash retainers and equity grants, and outlines a pay‑for‑performance program for executives that combines salary, annual bonuses and stock‑based incentives such as options, RSUs and performance stock units tied to ambitious share‑price hurdles. It also explains severance and change‑in‑control protections, a clawback policy, and the impact of the April 2026 spin‑off of First Tracks Biotherapeutics, including the CEO’s consulting arrangement and equity award treatment.
AnaptysBio, Inc. completed the spin-off of its biopharma operations into First Tracks Biotherapeutics, Inc. on April 20, 2026 and is now providing unaudited pro forma financial information reflecting the company after this separation.
The pro forma balance sheet as of December 31, 2025 shows a $100.0 million initial cash distribution to First Tracks, reducing AnaptysBio’s cash and cash equivalents from $238,196 to $138,196 (in thousands). Pro forma 2025 results convert a historical net loss of $13,232 (in thousands) into net income of $114,857 (in thousands), with collaboration revenue of $234,603 (in thousands) and basic pro forma earnings per share of $3.99.
Notes explain that First Tracks is treated as discontinued operations under ASC 205, that AnaptysBio anticipates approximately $7.0 million of additional non-recurring spin-off costs, and that a transition services agreement will add about $2.0 million to general and administrative expenses.
ANAPTYSBIO, INC President and CEO Daniel Faga reported a disposition of derivative securities. He returned 11,000 employee stock options, each exercisable for one share of common stock at $31.12 per share, to the issuer. The filing notes the option was fully vested and exercisable, and this was a non-market disposition back to the company rather than an open-market trade.
ANAPTYSBIO, INC director John A. Orwin reported option adjustments tied to a corporate separation. On April 20, 2026, he received several stock option grants for 8,250, 16,510, 16,510, 10,600, and 3,311 underlying AnaptysBio common shares at exercise prices between $10.87 and $32.17 per share, while corresponding options with higher exercise prices were disposed of back to the issuer.
Footnotes explain that, under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted into options for both companies, leading to these new AnaptysBio option positions. Some options are fully vested and exercisable, while others vest monthly starting February 6, 2026.
AnaptysBio director John P. Schmid reported multiple stock option adjustments tied to a corporate separation. On the reported date, he received several option grants to buy AnaptysBio common stock and simultaneously disposed of corresponding options back to the issuer.
A footnote explains that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into an option for First Tracks shares and an option for AnaptysBio shares. As a result, Schmid acquired new AnaptysBio options in amounts determined under that agreement. One referenced stock option is fully vested and exercisable, while another vests in 1/12 monthly installments starting on February 6, 2026, contingent on his continued service.
ANAPTYSBIO director Renton Hollings reported a series of stock option adjustments tied to a corporate separation. On April 20, 2026, he acquired multiple new options to buy AnaptysBio common stock and simultaneously disposed of corresponding older options back to the issuer. The footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into options over both companies’ shares. These are compensation and structural option changes, all held directly, and involve derivatives only rather than open-market trades in common stock.